Charles Schwab Investment Management Inc. Buys 42,587 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Charles Schwab Investment Management Inc. increased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 8.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 531,710 shares of the specialty pharmaceutical company's stock after purchasing an additional 42,587 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.86% of Jazz Pharmaceuticals worth $59,238,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Versant Capital Management Inc grew its stake in Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock worth $29,000 after buying an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in Jazz Pharmaceuticals during the second quarter worth about $29,000. EverSource Wealth Advisors LLC grew its stake in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock worth $30,000 after buying an additional 97 shares during the last quarter. GAMMA Investing LLC grew its stake in Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock worth $31,000 after buying an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP bought a new stake in Jazz Pharmaceuticals during the second quarter worth about $33,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Down 0.9 %

Shares of Jazz Pharmaceuticals stock traded down $1.05 during trading on Friday, hitting $121.59. 286,839 shares of the company were exchanged, compared to its average volume of 675,459. The firm has a market capitalization of $7.35 billion, a P/E ratio of 17.13, a price-to-earnings-growth ratio of 1.03 and a beta of 0.57. The firm's fifty day moving average price is $114.87 and its 200 day moving average price is $111.12. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17.

Insider Buying and Selling

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares of the company's stock, valued at $1,573,707.30. This trade represents a 8.85 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,110 shares of company stock valued at $720,160 in the last 90 days. 4.20% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have recently commented on JAZZ. Piper Sandler reissued an "overweight" rating and set a $163.00 price target (down from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Cantor Fitzgerald reissued an "overweight" rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Needham & Company LLC reissued a "buy" rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. TD Cowen decreased their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a research note on Thursday, November 7th. Finally, Royal Bank of Canada increased their price target on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a research note on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $175.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.